A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children (WEST-DBMD)

A Real-World, Multicenter Cohort Study on the Natural History of Duchenne and Becker Muscular Dystrophy in Children From Western China

This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.

Study Overview

• Status: Not yet recruiting
• Conditions: Muscular Dystrophy; Muscular Dystrophy, Duchenne; Muscular Dystrophy (DMD); Muscular Dystrophy, Becker
• Intervention / Treatment: Other: No interventions are applied; participants are followed for natural history observation only

Detailed Description

Detailed Description

1. Comprehensive Scientific Rationale and Knowledge Gap

   Duchenne Muscular Dystrophy (DMD) is characterized by a highly heterogeneous disease trajectory that is not fully captured by single-domain assessments. While individual milestones of functional decline, such as loss of ambulation or decline in forced vital capacity, are well-established, the dynamic and complex interrelationships between skeletal muscle pathology, systemic fat metabolism, cardiopulmonary function, and real-world functional performance over time remain poorly quantified. This lack of a systems-level, integrated understanding of DMD progression fundamentally limits the ability of clinicians to prognosticate for individual patients, optimally time interventions, and proactively tailor rehabilitation and management plans.

   Existing predictive models often rely on a limited set of functional or genetic parameters, failing to fully integrate the multi-systemic, physiological remodeling that occurs as the disease evolves. The central rationale for this study is that a more robust and clinically actionable understanding of progression can be achieved by synchronously capturing and integrating high-dimensional data across multiple physiological domains. Specifically, the detailed analysis of body composition-including the progressive atrophy of specific muscle groups, the patterns of ectopic fat infiltration within muscles and organs, and shifts in visceral adipose tissue distribution-is hypothesized to contain rich information reflective of the underlying molecular pathophysiology. We posit that the simultaneous longitudinal analysis of these compositional changes, in concert with traditional functional measures and advanced cardiopulmonary imaging, will reveal novel, synergistic biomarkers of disease progression that are not apparent when these domains are studied in isolation.

   This study is designed to address a critical knowledge gap: the system-level mapping of how different organ systems deteriorate in relation to one another in DMD. The evidence base generated by this research is expected to be crucial for refining prognostic accuracy, informing the timely adjustment of rehabilitative strategies, and enabling sophisticated patient stratification for future clinical trials.

2. Overall Research Strategy and Multidimensional Data Integration Framework

   The core innovation of this study lies not merely in the parallel collection of data, but in its sophisticated framework for integrating these multidimensional data streams to uncover their intrinsic relationships.

   Longitudinal Synchronization of Data Acquisition: A foundational element of the study design is the concurrent collection of all data streams (functional, compositional, imaging, laboratory) at predefined intervals throughout the study duration. This temporal alignment is critical for establishing sequence and potential causality between variables. It enables the investigation of key questions, such as whether changes in body composition precede or simply coincide with measurable declines in motor function or cardiopulmonary performance.

   Cross-Center Data Harmonization and Standardization: To ensure seamless data integration from multiple participating centers, the study will implement a comprehensive manual of standardized operating procedures (SOPs). These SOPs will govern every detail of all assessments and imaging protocols, encompassing patient preparation, device calibration, data acquisition, and post-processing pipelines. This rigorous quality control is a prerequisite for ensuring dataset integrity, minimizing inter-center variability, and guaranteeing that any observed differences in the final analysis reflect true biological heterogeneity rather than technical artifacts.

   Advanced Analytics and Modeling Methodology:

   Data Preprocessing and Feature Engineering: Raw data, particularly from imaging modalities, will be processed to extract quantitative, traceable features. Examples include deriving cross-sectional areas and fat fractions of specific muscle groups from magnetic resonance imaging (MRI), and calculating appendicular skeletal muscle index and fat mass index from body composition analysis.

   Exploratory Analysis and Hypothesis Generation: The initial analytical phase will employ exploratory data analysis techniques, including principal component analysis and unsupervised clustering algorithms, to identify naturally occurring patient subgroups within the data without a priori assumptions. This approach has the potential to uncover novel DMD phenotypes based on patterns of progression.

   Longitudinal Modeling: The core statistical analysis will utilize models specifically designed for repeated measures data. Mixed-effects models will be employed to quantify the intra- and inter-individual rates of change for each biomarker over time and to test associations between these rates of change and baseline covariates.

   Integrated Model Development and Validation: In the final phase, machine learning algorithms will be used to develop a composite model that leverages all available multimodal data to most accurately characterize disease progression trajectories. Model performance will be rigorously assessed via internal validation techniques. The primary output will be a "Disease Progression Atlas" that maps the sequence and interrelationships of multi-system physiological decline, rather than a single, simplified prognostic score.

3. End Goals and Long-Term Impact

The ultimate output of this research is intended to be a data-driven, comprehensive atlas of DMD disease progression. This atlas will qualitatively and quantitatively describe how different physiological systems deteriorate in relation to one another, defining both common and divergent pathways of functional decline.

The anticipated findings and long-term impacts of this study include:

Deepening Pathophysiological Understanding: Elucidating the pathophysiological links between muscle composition, systemic metabolism, and functional capacity in DMD, with a specific focus on the role of ectopic fat infiltration in the progression of muscle weakness and the development of cardiopulmonary insufficiency.

Providing a Resource for Future Clinical Development: Establishing a foundational evidence base to support future clinical trials by enabling better patient stratification and identifying sensitive, multi-domain composite endpoints that may be more responsive to therapeutic interventions.

Advancing Precision Medicine: Informing the development of personalized management algorithms by clarifying which combinations of biomarkers are most informative for predicting outcomes at specific disease stages. For instance, determining whether the fat fraction of thigh muscles at a given clinical node is a more powerful predictor of ambulatory loss in the subsequent year than standard functional walk tests.

In summary, this study is designed to generate a foundational dataset that will serve as a critical resource for refining prognostic accuracy and accelerating the advancement of personalized therapeutic and rehabilitative strategies in DMD. By adopting this systematic, multimodal approach, we aim to move beyond traditional descriptive natural history studies and provide a new paradigm for understanding and managing this complex disease.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

Study Locations

• China
  • Chengdu, China
    • West China Second University Hospital, Sichuan University
    • Contact: Xiaotang Cai, Degree（学位 / 职称）; Phone Number: +86 181 8060 9237; Email: cxt_1999@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

This is a multicenter observational natural history study of male children and adolescents with genetically confirmed Duchenne or Becker Muscular Dystrophy. Participants will be followed longitudinally to document the natural progression of muscle weakness, functional decline, and associated comorbidities. The study population includes individuals across a range of disease severity and ages, from early childhood to late adolescence.

Description

Inclusion Criteria:

• Male participants with genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD)
• Age range: 1 to 18 years old (adjust to your actual age limit)
• Ability to complete study assessments and follow-up visits
• Participants or legal guardians provide written informed consent

Exclusion Criteria:

• Participants with other neuromuscular disorders that may confound natural history data
• Participation in another interventional clinical trial that could affect disease progression
• Severe comorbidities that prevent completion of study assessments
• Inability to provide informed consent or comply with study procedures

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
DMD/BMD Cohort; Single cohort of children with Duchenne or Becker Muscular Dystrophy	Other: No interventions are applied; participants are followed for natural history observation only; This is an observational natural history study. No experimental interventions, treatments, or drugs are administered to participants. All data is collected through routine clinical care and follow-up assessments to document the natural progression of Duchenne and Becker Muscular Dystrophy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
NorthStar Ambulatory Assessment (NSAA) score	The NorthStar Ambulatory Assessment (NSAA) is a validated clinical scale to measure motor function in ambulatory boys with Duchenne or Becker Muscular Dystrophy.	Baseline and 24 months

Collaborators and Investigators

• Sponsor: West China Second University Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): April 20, 2026
• Primary Completion (Estimated): December 30, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: March 30, 2026
• First Submitted That Met QC Criteria: March 30, 2026
• First Posted (Actual): April 6, 2026

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: March 30, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Natural History; Multicenter Cohort Study; China; Predictive Model
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Nervous System Diseases; Muscular Diseases; Neuromuscular Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Muscular Disorders, Atrophic; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Muscular Dystrophies; Muscular Dystrophy, Duchenne
• Other Study ID Numbers: 2026002; Fund No. KL134 (Other Grant/Funding Number: West China Second Hospital of Sichuan University)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No